TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

SAREPTA THERAPS INC

Pharmaceuticals
Pharma

SAREPTA THERAPS INC is a pharmaceutical company with 3 FDA-approved products.

2016
Since
3
Drugs
-
Trials
5
Approved (2yr)

Key Drugs

EXONDYS 51
eteplirsen
Rare Disease
Dystrophin pre-mRNA 1 indications · 2016
VYONDYS 53
golodirsen
Rare Disease
Dystrophin pre-mRNA 1 indications · 2019
AMONDYS 45
casimersen
Rare Disease
Dystrophin pre-mRNA 1 indications · 2021

Recent Activity

AMONDYS 45 2026-01-06
Labeling
EXONDYS 51 2024-12-27
Labeling
AMONDYS 45 2024-07-11
Labeling
VYONDYS 53 2024-06-04
Labeling
VYONDYS 53 2024-06-04
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

No indication data

Pipeline Strength Pro

Loading...